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L-fucose did not show significant toxicity to animals so far we 
exam ined. In addition, it has been repor ted that normal human 
serum contains L-fucose in a small a mount [15]. T hus, L-fucose 
migh t be able to use for the regula tion of human allergic contact 
derm atitis. Moreover , L-fucose showed no suppressive effect on 
irritan t contact dermatitis and one might be able to differentiate 
allergic contact dermatitis from irritant contact dermati tis from 
t he effectiveness of L-fucose on the lesion. 
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